Micro Imaging Technology (MIT), a California-based public company trading under the symbol MMTC, announced the acquisition of Cellmyx, a company focused on regenerative medicine, cosmetic surgery, and adipose tissue transfer technologies. The transaction marks MIT’s latest move to build a broader platform in the aesthetics, cosmetic surgery, and regenerative medicine markets.
Cellmyx, formerly known as Millennium Medical Technologies, has operated in the cosmetic surgery industry for more than 25 years. Founded by Greg Miles, the company has developed a reputation for manufacturing medical tools used across cosmetic, orthopedic, pain management, and regenerative medicine applications. Its portfolio includes the IntelliFat® BOD™ system, which received U.S. Food and Drug Administration 510(k) clearance in 2023 for use in orthopedic, plastic, and cosmetic surgery procedures.
The acquisition follows MIT’s purchase of SaltMed/SaltFacial, which closed in December 2025. By combining Cellmyx and SaltMed/SaltFacial under one corporate umbrella, MIT aims to strengthen its manufacturing capabilities, expand its product offerings, and increase its reach in domestic and international markets.
Cellmyx specializes in autologous adipose grafting and transfer technologies that utilize a patient’s own fat tissue in various medical procedures. The company’s IntelliFat® BOD™ platform is designed to process and deploy adipose tissue for applications involving joint and ligament repair, recovery, and healing. Cellmyx also holds ISO 13485 and MDSAP certifications, supporting its position in the regulated medical device sector.
MIT said the acquisition enhances its presence in regenerative medicine while complementing the aesthetic treatment technologies offered through SaltMed/SaltFacial. The company plans to continue supporting existing customers while pursuing additional opportunities in the aesthetics and regenerative medicine sectors.
Cellmyx stated that its mission is to provide solutions for the harvesting, isolation, and deployment of tissue and cellular products while advancing innovation in cosmetic surgery and regenerative medicine. The company continues to develop technologies designed to improve adipose tissue transfer procedures and support physicians with advanced treatment options.
SaltFacial, meanwhile, offers a Class II medical device that combines sea salt resurfacing, ultrasound technology, and LED phototherapy. The treatment is designed to support skin rejuvenation by improving circulation, stimulating collagen production, and promoting skin health without some of the side effects commonly associated with laser and chemical-based treatments.
The addition of Cellmyx broadens MIT’s capabilities across both regenerative medicine and medical aesthetics, creating a larger platform positioned to serve physicians and patients through a wider range of technologies and treatment solutions.
KEY QUOTES:
“For 25 years the name ‘Millennium Medical Technologies Inc.’ DBA: Cellmyx, has been synonymous with quality and is known throughout the cosmetic surgical industry for product dependability. Company founder Greg Miles has strived to manufacture top of the line medical tools that run the gamut of application, aesthetics, and beyond. Regenerative intelliFat injectables offer a new frontier of research and invention, and Cellmyx is poised to lead the way in this exciting discipline.”
Micro Imaging Technology, Inc.
“MIT is committed and will continue to serve its existing and new customers with great service and support. MIT will continue to explore other opportunities in the aesthetics and regenerative space that can make a difference to humankind.”
Micro Imaging Technology, Inc.
